首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Inpatient Treatment of Community-Acquired Pneumonias with Integrative Medicine
【24h】

Inpatient Treatment of Community-Acquired Pneumonias with Integrative Medicine

机译:中西医结合治疗社区获得性肺炎

获取原文
           

摘要

Introduction.The aim of the presented observational case series was to evaluate the experience in treating patients with community-acquired pneumonia (CAP) within integrative medicine, particularly anthroposophic medicine in a well-experienced and specialized unit.Patients and Methods.Patients with proven CAP were evaluated (CAP-study group) based on a retrospective chart review. To estimate the severity of pneumonia, the pneumonia severity index (PSI) was applied. Treatment efficacy was evaluated regarding body temperature, CRP level, leukocytes blood count, the need to be treated on ICU, and mortality. Results were compared with the inpatient data of the Pneumonia PORT Validation Cohort.Results.15/18 patients of the CAP-study group belonged to risk class groups I–III (low and moderate risk), 2 patients to risk class IV, and one patient to risk class V (severe pneumonia). 16/18 patients were treated with anthroposophic medicine only and 2/18 got additionally antibiotic therapy (both of risk class IV). A significant reduction of body temperature, CRP level, and leukocytes blood count has been obtained by applying anthroposophic medicine, while neither complications nor pneumonia-related death occurred. Compared with the control group there was no significant difference in mortality rate, whereby no patient had to be treated on the ICU, but the duration of hospital stay was significantly longer in the presented series.Conclusion.Inpatient treatment of CAP with anthroposophic medicine without the use of antibiotics may achieve reasonable results in selected cases. Additional larger sized prospective controlled trials should further clarify the role of AM in the treatment of CAP.
机译:简介:本观察病例系列的目的是评估在经验丰富且专业的中西医结合治疗中合并社区获得性肺炎(CAP)患者的经验。患者和方法.CAP证实患者根据回顾性图表审查评估(CAP研究组)。为了评估肺炎的严重程度,应用了肺炎严重程度指数(PSI)。评估了体温,CRP水平,白细胞血球计数,需要加护病房(ICU)和死亡率的治疗效果。将结果与肺炎PORT验证队列的住院数据进行比较。结果:CAP研究组的15/18病人属于I–III级风险(低和中度风险),2名属于IV级风险,1名患者患有V级风险(严重肺炎)。 16/18的患者仅接受了人类营养药物治疗,而2/18的患者另外接受了抗生素治疗(均为危险级别IV)。通过应用人类营养药物可以显着降低体温,CRP水平和白细胞血细胞计数,而并发症和与肺炎相关的死亡均未发生。与对照组相比,死亡率没有显着差异,因此无需在ICU上接受治疗,但在所提出的系列中住院时间显着延长。结论。在某些情况下,使用抗生素可能会取得合理的结果。其他较大规模的前瞻性对照试验应进一步阐明AM在CAP治疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号